中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

34 records (took 0.019 seconds)

    HUMAN ANTIBODIES TO PD-L1
    13.
    发明申请
    HUMAN ANTIBODIES TO PD-L1 有权

    公开(公告)号：US20210380702A1

    公开(公告)日：2021-12-09

    申请号：US17399829

    申请日：2021-08-11

    Applicant: Regeneron Pharmaceuticals, Inc.

    Inventor： Nicholas J. Papadopoulos ,  Andrew J. Murphy ,  Gavin Thurston ,  Ella Ioffe ,  Elena Burova

    IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  C07K16/22 ,  C07K16/30

    Abstract: The present invention provides antibodies that bind to the T-cell co-inhibitor ligand programmed death-ligand1 (PD-L1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-L1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-L1 and a second binding specificity that binds to a tumor cell antigen, an infected cell-specific antigen, or a T-cell co-inhibitor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-L1 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.

    Human antibodies to PD-1
    16.
    发明授权
    Human antibodies to PD-1 有权

    公开(公告)号：US10737113B2

    公开(公告)日：2020-08-11

    申请号：US15905685

    申请日：2018-02-26

    Applicant: Regeneron Pharmaceuticals, Inc.

    Inventor： Nicholas J. Papadopoulos ,  Andrew J. Murphy ,  Gavin Thurston ,  Ella Ioffe ,  Elena Burova

    IPC: C07K16/28 ,  C12N15/13 ,  C12N15/63 ,  A61K39/395 ,  A61N5/10 ,  A61K45/06 ,  A61K39/00

    Abstract: The present invention provides antibodies that bind to the T-cell co-inhibitor programmed death-1 (PD-1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-1 and a second binding specificity that binds to an autoimmune tissue antigen, another T-cell co-inhibitor, an Fc receptor, or a T-cell receptor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-1 activity, thus providing a means of treating a disease or disorder such as cancer or a chronic viral infection. In other embodiments, the antibodies are useful for enhancing or stimulating PD-1 activity, thus providing a means of treating, for example, an autoimmune disease or disorder.

Patent Agency Ranking